News
06-06-2010, 11:52 PM
Incyte Corporation announced today additional positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 66 patients with HER2-positive metastatic breast cancer during a poster session at the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL, June 4 to June 8, 2010.
More... (http://www.news-medical.net/news/20100607/Incyte-presents-additional-results-from-INCB7839-Phase-III-trial-for-HER2-positive-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20100607/Incyte-presents-additional-results-from-INCB7839-Phase-III-trial-for-HER2-positive-metastatic-breast-cancer.aspx)